- Home
- RIOT vs RNA Comparison
RIOT vs RNA Comparison
Compare RIOT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIOT
- RNA
- Stock Information
- Founded
- RIOT 2000
- RNA 2012
- Country
- RIOT United States
- RNA United States
- Employees
- RIOT N/A
- RNA N/A
- Industry
- RIOT Retail: Computer Software & Peripheral Equipment
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- RIOT Technology
- RNA Health Care
- Exchange
- RIOT Nasdaq
- RNA Nasdaq
- Market Cap
- RIOT 4.0B
- RNA 3.7B
- IPO Year
- RIOT N/A
- RNA 2020
- Fundamental
- Price
- RIOT $7.41
- RNA $31.60
- Analyst Decision
- RIOT Strong Buy
- RNA Strong Buy
- Analyst Count
- RIOT 13
- RNA 12
- Target Price
- RIOT $17.42
- RNA $68.25
- AVG Volume (30 Days)
- RIOT 23.9M
- RNA 1.3M
- Earning Date
- RIOT 04-30-2025
- RNA 05-08-2025
- Dividend Yield
- RIOT N/A
- RNA N/A
- EPS Growth
- RIOT N/A
- RNA N/A
- EPS
- RIOT 0.34
- RNA N/A
- Revenue
- RIOT $376,658,000.00
- RNA $10,897,000.00
- Revenue This Year
- RIOT $94.00
- RNA N/A
- Revenue Next Year
- RIOT $2.60
- RNA $230.08
- P/E Ratio
- RIOT $21.53
- RNA N/A
- Revenue Growth
- RIOT 34.20
- RNA 13.98
- 52 Week Low
- RIOT $6.36
- RNA $21.56
- 52 Week High
- RIOT $15.87
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- RIOT 37.75
- RNA 50.31
- Support Level
- RIOT $7.50
- RNA $30.12
- Resistance Level
- RIOT $8.83
- RNA $33.13
- Average True Range (ATR)
- RIOT 0.52
- RNA 2.14
- MACD
- RIOT 0.12
- RNA 0.14
- Stochastic Oscillator
- RIOT 10.69
- RNA 35.92
About RIOT Riot Platforms Inc.
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.